GC Cell Corporation (KOSDAQ:144510)

Market Cap	342.62B
Revenue (ttm)	170.46B
Net Income (ttm)	-85.29B
Shares Out	15.03M
EPS (ttm)	-5,676.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	35,108
Average Volume	94,165
Open	23,150
Previous Close	22,800
Day's Range	23,150 - 24,450
52-Week Range	16,940 - 26,950
Beta	1.00
RSI	54.28
Earnings Date	Nov 14, 2025

About GC Cell

GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC. GC Cell Corporation has strategic agreement with Lukas Biomedical Co., Ltd. to develop Cell therapy. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in November 2021. GC Cell Corporation was founded in 2011 and is based in Yongin-si, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2011
• Employees: 709
• Stock Exchange: KOSDAQ
• Ticker Symbol: 144510

Financial Performance

In 2024, GC Cell's revenue was 174.45 billion, a decrease of -6.98% compared to the previous year's 187.54 billion. Losses were -73.90 billion, 42368.9% more than in 2023.